Metalloreductase STEAP2 (STEAP2)

Metalloreductase STEAP2 is a membrane-embedded, NADPH-dependent oxidoreductase belonging to the STEAP family. It possesses six transmembrane domains and localizes primarily to the plasma membrane, Golgi complex, and vesicular tubular structures. Physiologically, STEAP2 catalyzes the reduction of ferric (Fe3+) and cupric (Cu2+) ions, supporting cellular iron and copper uptake. The enzyme acts by transporting electrons from intracellular NADPH, via FAD and a heme cofactor, across the membrane to reduce extracellular metal-chelates[2][3][4][5]. STEAP2 is frequently overexpressed in prostate cancer and implicated in tumor progression, proliferation, migration, and invasion, making it a putative therapeutic target and potential biomarker for aggressive forms of cancer. Its structure has been shown to include a trimeric assembly, with functional electron transfer supported by domain-swapping, but drug interactions or direct inhibitors are not currently established[1][2][3].

Other names

Prostate cancer-associated protein 1Six-transmembrane epithelial antigen of prostate 2SixTransMembrane protein of prostate 1PCANAP1STAMP1STMPIPCA-1PUMPCnIPCA1protein up-regulated in metastatic prostate cancerSTEAP family member 2

Reduction of Fe3+-chelates and Cu2+ to facilitate cellular iron and copper uptake